Clinical Trial Update: Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

View source ↗

Summary

Expanded access use of nogapendekin-alfa inbakicept to reverse and maintain absolute lymphocyte count in patients with lymphopenia induced by chemotherapy, immu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphopenia

Drugs mentioned

• Nogapendekin-alfa Inbakicept

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Lymphopenia | Status: AVAILABLE